Article
Oncology
Qihua He, Jun Liu, Xiuyu Cai, Caichen Li, Hengrui Liang, Bo Cheng, Xiaojun Xia, Minzhang Guo, Peng Liang, Ran Zhong, Feng Li, Ziwen Yu, Yi Zhao, Limin Ou, Shan Xiong, Jianfu Li, Jianrong Zhang, Jianxing He, Wenhua Liang
Summary: This study compared the clinical effectiveness of different first-generation EGFR-TKIs as adjuvant therapy in early-stage EGFR mutated NSCLC patients, showing comparable results in DFS for gefitinib, erlotinib, and icotinib groups, as well as no significant differences in treatment failure patterns among the different TKIs.
TRANSLATIONAL LUNG CANCER RESEARCH
(2021)
Editorial Material
Oncology
Xiuning Le, Monique B. Nilsson, Jacqulyne P. Robichaux, John V. Heymach
Summary: The ARTEMIS study showed that combining the VEGF inhibitor bevacizumab with the EGFR inhibitor erlotinib can significantly improve progression-free survival in patients with EGFR mutant non-small-cell lung cancer, especially in those with brain metastases and the EGFR L858R mutation. This suggests the potential benefits of tailored use of VEGF/EGFR combinations in this patient population.
Article
Oncology
Yixiang Zhu, Ye Zhang, Xingsheng Hu, Mingzhao Wang, Hongyu Wang, Yutao Liu
Summary: ICI combined with chemotherapy +/- bevacizumab may be an effective and safe treatment option for EGFR/ALK-positive NSCLC patients, especially for those who progress after previous TKI therapy.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2022)
Article
Cell Biology
Alessandro Leonetti, Mjriam Capula, Roberta Minari, Giulia Mazzaschi, Alessandro Gregori, Btissame El Hassouni, Filippo Papini, Paola Bordi, Michela Verze, Amir Avan, Marcello Tiseo, Elisa Giovannetti
Summary: Our study found that patients with an increase in miR-21 levels after two months of EGFR-TKI treatment were more likely to experience disease stability/progression. Patients who experienced clinical benefit lasting at least six months showed higher levels of circulating miR-21.
Article
Biochemistry & Molecular Biology
Chia-Hung Chen, Bo-Wei Wang, Yu-Chun Hsiao, Chun-Yi Wu, Fang-Ju Cheng, Te-Chun Hsia, Chih-Yi Chen, Yihua Wang, Zhang Weihua, Ruey-Hwang Chou, Chih-Hsin Tang, Yun-Ju Chen, Ya-Ling Wei, Jennifer L. Hsu, Chih-Yen Tu, Mien-Chie Hung, Wei-Chien Huang
Summary: Upregulation of active sodium/glucose co-transporter 1 (SGLT1) was found to confer the development of acquired EGFR TKI resistance and was correlated with poorer clinical outcomes in NSCLC patients. Blockade of SGLT1 overcame this resistance by reducing glucose uptake in NSCLC cells, suggesting a potential strategy to improve the therapeutic efficacy of EGFR TKIs in NSCLC patients.
Article
Biochemistry & Molecular Biology
Zhenzhen Pan, Kai Wang, Xiniao Wang, Zhirong Jia, Yuqi Yang, Yalei Duan, Lianzhan Huang, Zhuo-Xun Wu, Jian-ye Zhang, Xuansheng Ding
Summary: This study reveals a common molecular mechanism underlying EGFR-TKIs resistance in non-small cell lung cancer, involving cholesterol accumulation, EGFR/Src/Erk/SP1 axis-mediated ERR alpha re-expression and subsequent cell proliferation. Lowering cholesterol levels and downregulating ERR alpha can overcome resistance to gefitinib and osimertinib.
Article
Oncology
Liping Yang, Panpan Xu, Mengyue Li, Menglu Wang, Mengye Peng, Ying Zhang, Tingting Wu, Wenjie Chu, Kezheng Wang, Hongxue Meng, Lingbo Zhang
Summary: This study evaluated the predictive efficacy of baseline F-18-FDG PET/CT-based radiomics analysis for EGFR mutation status, mutation site, and the survival benefit of targeted therapy in NSCLC patients. The results showed that PET/CT-based radiomics analysis could be a useful approach to predict EGFR mutation status and mutation site, and could serve as a predictor for the patients' survival outcome of targeted therapy.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Daoan Cheng, Banglu Wang, Lige Wu, Rui Chen, Weiqing Zhao, Cheng Fang, Mei Ji
Summary: Lung cancer is the primary cause of cancer-related deaths worldwide. The use of EGFR tyrosine kinase inhibitors has improved survival rates for patients with EGFR-mutated non-small cell lung cancer. However, resistance to these inhibitors, like other anticancer drugs, inevitably develops over time. Exosomes, extracellular vesicles carrying non-coding RNAs, have been found to play a role in the development of EGFR-TKIs resistance. This review provides an overview of the current research on exosomal non-coding RNAs mediating EGFR-TKIs resistance in EGFR-mutated NSCLC, and suggests potential applications in monitoring therapy and developing new treatment strategies.
Article
Multidisciplinary Sciences
Yen-Hsiang Huang, Jeng-Sen Tseng, Kuo-Hsuan Hsu, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J. W. Chen, Tsung-Ying Yang, Gee-Chen Chang
Summary: The study demonstrated that sequential osimertinib treatment following first-generation or second-generation EGFR-TKIs provided good clinical efficacy for EGFR-mutant NSCLC patients with acquired T790M mutation, prolonging progression-free survival and overall survival.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Xiao Liang, Wei Zhang, Jun Li, Jing Zhu, Jun Shao, Jing Wang, Hongshuai Wu, Jiali Dai, Jiali Xu, Wei Wang, Renhua Guo
Summary: This study found that concurrent detection of EGFR mutation in tumor tissue and plasma is an independent prognostic factor for first-line EGFR-TKIs treatment in EGFR-mutated non-small cell lung cancer (NSCLC) patients. Combination therapy may be a promising approach to improve the outcome for these patients.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Dan Yan
Summary: EGFR-mutant NSCLCs have limited response to immune checkpoint inhibitors, possibly due to the non-inflamed tumor immune microenvironment. However, a small population of patients still exhibit durable response to this treatment.
Article
Oncology
Shang-Gin Wu, Chien-Hung Gow, Yi-Ling Chen, Yi-Nan Liu, Meng-Feng Tsai, Jin-Yuan Shih
Summary: This study investigated the efficacy of EGFR-tyrosine kinase inhibitors (TKIs) and the acquisition of T790M mutation in different subtypes of EGFR exon 19 deletion (Del-19) in advanced non-small-cell lung cancer (NSCLC). The results showed no significant differences in response rates between different Del-19 subtypes, but patients with indel E746 had longer progression-free survival (PFS) and overall survival (OS), while those with non-LRE deletions had the shortest survival. There were also no significant differences in the rates of T790M acquisition and the effectiveness of third-generation EGFR-TKIs in different Del-19 subgroups.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Oncology
Li Ma, Haoyang Li, Dongpo Wang, Ying Hu, Mengjun Yu, Quan Zhang, Na Qin, Xinyong Zhang, Xi Li, Hui Zhang, Yuhua Wu, Jialin Lv, Xinjie Yang, Ruoying Yu, Shucai Zhang, Jinghui Wang
Summary: Dynamic cfDNA analysis using NGS can predict efficacy and resistance mechanisms of third-generation EGFR TKIs in NSCLC patients. Clearance of cfDNA and T790M level are significantly associated with clinical outcomes. The most common resistant mutation of third-generation TKIs is EGFR C797S.
FRONTIERS IN ONCOLOGY
(2021)
Article
Immunology
Dehua Liao, Lun Yu, Shanshan Chen, Ni Liu, Jingyi Tang, Nong Yang
Summary: This study aimed to evaluate the safety profile of sequential treatment of TKIs and ICIs in advanced NSCLC. The most common adverse events were decreases in hemoglobin and liver toxicity. Although the adverse events did not significantly increase in the sequential treatment pattern, careful consideration should be given to the increased risk of some adverse events when TKIs were pre/post-treated with ICIs.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Multidisciplinary Sciences
Mengmeng Niu, Jing Xu, Yang Liu, Yuhuang Li, Tao He, Liangping Ding, Yajun He, Yong Yi, Fengtian Li, Rongtian Guo, Ya Gao, Rui Li, Luping Li, Mengyuan Fu, Qingyong Hu, Yangkun Luo, Chunyan Zhang, Kewei Qin, Jianqiao Yi, Shuhan Yu, Jian Yang, Hu Chen, Liang Wang, Zhonghan Li, Biao Dong, Shiqian Qi, Liang Ouyang, Yujun Zhang, Yang Cao, Zhi-Xiong Jim Xiao
Summary: The study shows that FBXL2 targets EGFR and TKI-resistant mutants for degradation, which inhibits EGFR-driven NSCLC growth and TKI resistance.
NATURE COMMUNICATIONS
(2021)